Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Luis Isola, MD

Icahn School of Medicine at Mount Sinai

Intervention

arsenic trioxide(drug)

Enrollment

25 enrolled

Eligibility

18 years · All sexes

Timeline

2001

Study locations (1)

• Mount Sinai Medical Center, New York, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell prolymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT05418088
  Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
  Sumithira Vasu
• ACTIVE NOT RECRUITINGPHASE1NCT02153580
  Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
  City of Hope Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT02007044
  Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT01589302
  PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
  Kami Maddocks, MD

See all trials for B-cell prolymphocytic leukemia →